Pharma BD Deal Intelligence
Biogen's $1 billion bet on RayThera lands as a pipeline pre-buy, not a proven win: the deal is mostly clinical- and regulatory-milestone payments tied to an oral anti-inflammatory that hadn't even entered Phase 1 at signing, making this Biogen's second 2026 acquisition to prioritize immunology optionality over de-risked assets.
Immunology pipeline expansion via preclinical small-molecule bolt-on
Full analysis, sources & comparables →On June 17, 2026, Biogen agreed to acquire RayThera Inc., a private US biotech developing small-molecule therapies in immunology, for up to $1 billion comprising an upfront payment and predominantly clinical- and regulatory-milestone payments. RayThera's portfolio includes multiple anti-inflammatory assets for immune-mediated conditions, with its lead candidate expected to enter Phase 1 in early Q3 2026. The transaction is expected to close in Q3 2026, after which Biogen will lead development, manufacturing and global commercialization. It is Biogen's second acquisition of 2026.
RayThera develops oral small-molecule anti-inflammatory therapies for immune-mediated conditions across multiple indications. The lead candidate is expected to enter Phase 1 in early Q3 2026; specific targets/indications are undisclosed. The acquisition expands Biogen's immunology pipeline.
Biogen agrees to acquire RayThera for up to $1B (upfront + clinical/regulatory milestones); close expected Q3 2026.
Lead asset is preclinical (Phase 1 expected Q3 2026); value is milestone-weighted and contingent on customary closing conditions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / RayThera Inc. (this deal) | 2026 | $1.0B | 52 |
| Biogen Inc. / Reata Pharmaceuticals | 2023 | $7.3B | 73 |
| Biogen Inc. / Human Immunology Biosciences | 2024 | $1.1B | 68 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / Nightstar Therapeutics | 2019 | $800M | — |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
| Biogen Inc. / Vanqua Bio, Inc. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2026 deals · Biogen Inc. deals · Immunology deals